首页>投融资
Vedanta Biosciences
未透露
Vedanta Biosciences Inc is a spin-off from Yale University, a subsidiary of PureTech Health, a biotechnology company pioneering the development of defined bacterial consortia as oral therapies that modulate the human microbiome to treat disease.In January 2021, Pfizer Inc invested $25 million in Vedanta Biosciences Inc.In July 2021, Vedanta Biosciences closed of a $68 million Series D financing.In January 2021, Pfizer Invested $25 million in Vedanta Biosciences which focused on developing a new category of therapies for immune-mediated diseases based on rationally defined consortia of human microbiome-derived bacteria.In June 2020, the company raised an additional $12 million series C/C-2 financing round, bringing the total capital to $71.1 million.In September 2019, the company raised a $16.6 million series C-2 financing round, bringing the total capital raised in its series C and C-2 round to $62.1 million.In May 2018, the company raised an additional $18
基本信息
-
公司全称Vedanta Biosciences Inc
-
类型免疫疗法开发商
-
产业领域医药研发/制造、化学&生物药
-
公司人数51~100人
-
地址19 BLACKSTONE STREET,THIRD FLOOR CAMBRIDGE MASSACHUSETTS 02139; US; Telephone: +18577061427;
-
联系电话(857)706-1427
-
邮箱info@vedantabio.com
-
成立时间2010-01-01
投融资
-
2023-04-25未透露1.065亿美元Bill and Melinda Gates FoundationAXA IM AltsSeventure PartnersQUAD辉瑞Revelation PartnersAtlantic NeptuneReimagined VenturesPEAK6Hambro PerksK2 HealthVenturesSkyviews Life ScienceAMR Action FundKorea Investment PartnersKorea Investment＆SecuritiesPureTech Health
-
2021-07-21D轮6800万美元JSR CorporationHealth for Life Capital fundMagnetar CapitalVerition Fund ManagementSymbiosisSkyviews Life ScienceShumway CapitalRock Springs Capital
-
2021-01-21未透露2500万美元辉瑞
-
2020-09-30未透露7690万美元Biomedical Advanced Research and Development Authority
-
2019-12-05捐赠/众筹/授予580万美元CARB-X
-
2019-09-23C+轮1660万美元QUAD易凯资本Partners InvestmentSV InvestmentSymbiosisFC CapitalShinhan Capital
-
2019-05-13C轮4550万美元Shumway CapitalJSR CorporationPartners Investment
-
2018-12-25C轮2700万美元Bill and Melinda Gates FoundationSeventure Partners百时美施贵宝InvescoRock Springs CapitalPureTech Health
-
2018-07-10捐赠/众筹/授予未透露Crohn's & Colitis Foundation
-
2017-11-03捐赠/众筹/授予540万美元CARB-X
-
2016-06-06E~PreIPO5000万美元Rock Springs CapitalInvescoPureTech Health
- 加载更多
相关投融资企业
A轮
Ouro Medicines是一家免疫重置公司，通过结合科学专业知识、通过临床推进细胞耗竭疗法的跟踪记录以及强大的管道来正面应对慢性免疫介导的疾病。Ouro最领先的候选产品是OM336，这是一种最近从康诺亚生物获得许可的BCMA靶向的双特异性TCE。
A轮
RhyGaze开发一种新的基因疗法，旨在恢复患者的视力。该公司的治疗技术将光传感器基因专门传递给失去光敏感性的视锥细胞，并修复其检测光的能力，使医疗保健行业能够为失明患者提供视力恢复。
未公开
Thetis Pharmaceuticals LLC is a pharmaceutical company focused on the development of prescription drugs for diabetes, hypertriglyceridemia and dyslipidemia. Thetis's proprietary HEALER technology (High Efficiency Amino Lipid Enabled Release) uses transformative ionic chemistry to revitalize proven therapeutic agents and generated solid, stable APIs.In July 2021, Thetis Pharmaceuticals LLC announced the launch of a new program in cancer TP-317, which is a Resolvin E1 therapy for the treatment of solid tumour cancers published in the Journal of Experimental Medicine.In May 2013, the company raised $5.7 million through a series A financing.In September 2011, Thetis secured first round funding. At that time, the company planned to secure additional capital in the second half of 2012
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息